Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Method for inhibiting propagation of virus and anti-viral agent|
|Abstract:||Described is a method for inhibiting propagation of virus which comprises delivering one or more oligodeoxynucleotides or polydeoxynucleotides to a place where a messenger RNA (mRNA) generated on propagation of the virus exists, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to the mRNA, the structure being capable of hybridizing to the mRNA. Also described is an anti-viral agent which comprises an effective amount of one or more oligodeoxynucleotides or polydeoxynucleotides with a conventional liquid vehicle or excipient, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to an mRNA generated on propagation of the virus, the structure being capable of hybridizing to the mRNA. The method and the agent can widely be applied to the treatment of viral diseases.|
|Inventor(s):||Kaji; Akira (Higashikurume-shi, Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Dosage form; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.